2019 ACNM Spring Newsletter CME/SAM Cases: Which is the Best Radiopharmaceutical to Use for Diagnosing or Confirming this Focal Brain Abnormality?
Release Date: 5/1/2019
Expiration Date: 5/31/2022
SNMMI/ACNM Members: $0
Non-Members: $20
Continuing Education Credit Information
ABNM SAM Credit
The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment. 1.0 SAMs have been awarded for this activity.
AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. SNMMI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Objectives
At the completion of this activity, the participant will be able to:
1. Determine the appropriate radiopharmaceutical for different brain entities.
2. Discuss important correlative anatomic imaging findings in the brain.
3. Compare various benign versus malignant brain findings.
Target Audience
The Life Long Learning and Self-Assessment activity is designed for all nuclear medicine physicians and radiologists.
Presenter
Twyla B. Bartel, DO, MBA, FACNM
Financial Disclosure
In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the speaker has indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.
Contact Information
For questions please contact Lisa Dickinson, Associate Director of Education at ldickinson@snmmi.org or 703-652-6783.
